Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 1/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 6/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | TARBP2 | Q15633 | 1/20 | 0.38 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | DHODH | Q02127 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29764175 | 1.00 | BRD4 (0.47) | BRD4HSD17B10KDM4EALDH1A1CYP1A2 | |
| SCHEMBL31288369 | 0.88 | BRD4 (0.49) | BRD4HSD17B10KDM4EALDH1A1CYP1A2 | |
| SCHEMBL25389928 | 0.88 | BRD4 (0.49) | BRD4HSD17B10KDM4EALDH1A1CYP1A2 | |
| SCHEMBL29764161 | 0.85 | BRD4 (0.47) | BRD4HSD17B10KDM4EALDH1A1CYP1A2 | |
| SCHEMBL21831297 | 0.85 | BRD4 (0.47) | BRD4HSD17B10KDM4EALDH1A1CYP1A2 | |
| SCHEMBL25388840 | 0.85 | BRD4 (0.50) | BRD4HSD17B10KDM4EALDH1A1CYP1A2 | |
| SCHEMBL25387448 | 0.83 | BRD4 (0.45) | BRD4HSD17B10KDM4EALDH1A1CYP1A2 | |
| SCHEMBL29922567 | 0.82 | KMT2A (0.49) | BRD4KDM4EALDH1A1CYP1A2CYP2C19 | |
| SCHEMBL15574689 | 0.82 | KMT2A (0.49) | BRD4KDM4EALDH1A1CYP1A2CYP2C19 | |
| SCHEMBL19372549 | 0.82 | TARBP2 (0.44) | BRD4HSD17B10KDM4ECYP1A2HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4081523-B1 | SUBSTITUTED BICYCLIC PIPERIDINE DERIVATIVES USEFUL AS T CELL ACTIVATORS | BRISTOL MYERS SQUIBB CO (US) | 2024-12-25 | — | — | EP | disclosed |
| CN-112654621-B | Substituted naphthyridinone compounds useful as T cell activators | 百时美施贵宝公司 | 2024-05-14 | — | — | CN | disclosed |
| US-11964973-B2 | Substituted bicyclic compounds useful as T cell activators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2024-04-23 | — | — | US | disclosed |
| US-11866430-B2 | Naphthyridinone compounds useful as T cell activators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2024-01-09 | — | — | US | disclosed |
| CN-112585139-B | Naphthyridinone compounds as T cell activators | 百时美施贵宝公司 | 2023-12-01 | — | — | CN | disclosed |
| EP-3814348-B9 | SUBSTITUTED NAPHTHYRIDINONE COMPOUNDS USEFUL AS T CELL ACTIVATORS | BRISTOL MYERS SQUIBB CO (US) | 2023-11-01 | — | — | EP | disclosed |
| WO-2023184327-A1 | KINASE INHIBITORS, PREPARATION METHODS AND USES THEREOF | InventisBio Co., Ltd. (CN) | 2023-10-05 | — | — | WO | disclosed |
| EP-3814348-B1 | SUBSTITUTED NAPHTHYRIDINONE COMPOUNDS USEFUL AS T CELL ACTIVATORS | BRISTOL MYERS SQUIBB CO (US) | 2023-08-02 | — | — | EP | disclosed |
| US-11713316-B2 | Substituted naphthyridinone compounds useful as T cell activators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2023-08-01 | — | — | US | disclosed |
| US-11713316-B2 | Substituted naphthyridinone compounds useful as T cell activators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2023-08-01 | — | — | US | disclosed |
| CN-112654621-A | Substituted naphthyridinone compounds useful as T cell activators | 百时美施贵宝公司 | 2021-04-13 | — | — | CN | disclosed |
| CN-112585139-A | Nalidinone compounds as T cell activators | 百时美施贵宝公司 | 2021-03-30 | — | — | CN | disclosed |
| US-10954238-B1 | Substituted naphthyridinone compounds useful as T cell activators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2021-03-23 | — | — | US | disclosed |
| US-10954238-B1 | Substituted naphthyridinone compounds useful as T cell activators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2021-03-23 | — | — | US | disclosed |
| CN-111471059-A | PDE9 inhibitors and uses thereof | 南京药捷安康生物科技有限公司 | 2020-07-31 | — | — | CN | disclosed |
| WO-2020151636-A1 | PDE9 INHIBITOR AND USE THEREOF | 南京药捷安康生物科技有限公司 | 2020-07-30 | — | — | WO | disclosed |
| US-10669272-B2 | Substituted naphthyridinone compounds useful as T cell activators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2020-06-02 | — | — | US | disclosed |
| US-10669272-B2 | Substituted naphthyridinone compounds useful as T cell activators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2020-06-02 | — | — | US | disclosed |
| US-20200109140-A1 | SUBSTITUTED NAPHTHYRIDINONE COMPOUNDS USEFUL AS T CELL ACTIVATORS | SYNGENE INTERNATIONAL LIMITED (IN) | 2020-04-09 | — | — | US | disclosed |
| US-20200109140-A1 | SUBSTITUTED NAPHTHYRIDINONE COMPOUNDS USEFUL AS T CELL ACTIVATORS | SYNGENE INTERNATIONAL LIMITED (IN) | 2020-04-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200109140-A1 | SUBSTITUTED NAPHTHYRIDINONE COMPOUNDS USEFUL AS T CELL ACTIVATORS | DGKZ, DGKA, DGKG | BRD4 587/4885HSD17B10 3498/4885KDM4E 1982/4885 |
| US-11713316-B2 | Substituted naphthyridinone compounds useful as T cell activators | DGKZ, DGKA, DGKG | BRD4 587/4885HSD17B10 3498/4885KDM4E 1982/4885 |
| US-11866430-B2 | Naphthyridinone compounds useful as T cell activators | DGKZ, DGKA, DGKG | BRD4 607/4885HSD17B10 3108/4885KDM4E 2027/4885 |
| US-10669272-B2 | Substituted naphthyridinone compounds useful as T cell activators | DGKZ, DGKA, DGKG | BRD4 587/4885HSD17B10 3498/4885KDM4E 1982/4885 |
| US-11964973-B2 | Substituted bicyclic compounds useful as T cell activators | DGKA, DGKZ, DGKK | BRD4 593/4885HSD17B10 4183/4885KDM4E 2817/4885 |
| US-10954238-B1 | Substituted naphthyridinone compounds useful as T cell activators | DGKZ, DGKA, DGKG | BRD4 587/4885HSD17B10 3498/4885KDM4E 1982/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.